Visium Asset Management’s Salix Pharmaceuticals SLXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
– Sell
-3,076,092
Closed -$354M – 1322
2014
Q4
$354M Buy
3,076,092
+774,463
+34% +$93.8M 4.99% 3
2014
Q3
$360M Buy
2,301,629
+486,630
+27% +$70.5M 5.31% 1
2014
Q2
$224M Buy
1,814,999
+50,433
+3% +$5.57M 3.48% 5
2014
Q1
$183M Buy
1,764,566
+724,497
+70% +$74.2M 2.96% 6
2013
Q4
$93.5M Buy
1,040,069
+490,069
+89% +$39.1M 1.84% 6
2013
Q3
$36.8M Buy
+550,000
New +$37.9M 0.83% 24

Other funds holding SLXP

Visium Asset Management's SLXP Position: Q1 2015 in Review

Visium Asset Management sold out of Salix Pharmaceuticals (SLXP) in Q1 2015, closing a stake of 3,076,092 shares — an estimated $354M sold.

Visium Asset Management first reported a position in SLXP in Q3 2013 and held it in 6 quarters. The position peaked at $360M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Visium Asset Management reported no remaining Salix Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Visium Asset Management sold 3,076,092 Salix Pharmaceuticals shares in Q1 2015, an estimated $354M.
  • Visium Asset Management first reported a position in Salix Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Visium Asset Management's Salix Pharmaceuticals position peaked at $360M in Q3 2014.
  • 298 funds tracked by Wall St. Rank held Salix Pharmaceuticals as of Q1 2015.

Based on Visium Asset Management's 13F filing for Q1 2015, filed 15 May 2015.